Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04629729
PHASE1

FT819 in Subjects With B-cell Malignancies

Sponsor: Fate Therapeutics

View on ClinicalTrials.gov

Summary

This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed/refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.

Official title: A Phase I Study of FT819 in Subjects With B-cell Malignancies

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

54

Start Date

2021-07-12

Completion Date

2039-09-30

Last Updated

2026-03-19

Healthy Volunteers

No

Interventions

DRUG

FT819

Experimental Interventional Therapy

DRUG

Cyclophosphamide

Lympho-conditioning agent

DRUG

Fludarabine

Lympho-conditioning agent

DRUG

IL-2

Biologic response modifier

DRUG

Bendamustine

Lympho-conditioning agent

Locations (18)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Mayo Arizona

Phoenix, Arizona, United States

UC Davis

Davis, California, United States

Scripps Green Hospital

La Jolla, California, United States

UCLA Ronald Reagan Medical Center

Los Angeles, California, United States

Stanford Cancer Institute

Palo Alto, California, United States

University of Florida

Gainesville, Florida, United States

Mayo Florida

Jacksonville, Florida, United States

University of Iowa

Iowa City, Iowa, United States

The University of Kansas Cancer Center

Westwood, Kansas, United States

Norton Cancer Institute, St. Matthews Campus

Louisville, Kentucky, United States

Mayo Minnesota

Rochester, Minnesota, United States

University of Nebraska Medical Center

Omaha, Nebraska, United States

Hackensack University Medical Center

Hackensack, New Jersey, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Oregon Health & Sciences University

Portland, Oregon, United States

MD Anderson Cancer Center

Houston, Texas, United States

University of Wisconsin-Madison

Madison, Wisconsin, United States